Solid Biosciences (SLDB)
(Delayed Data from NSDQ)
$6.82 USD
-0.01 (-0.15%)
Updated Aug 4, 2025 04:00 PM ET
After-Market: $6.82 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SLDB 6.82 -0.01(-0.15%)
Will SLDB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SLDB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SLDB
Wall Street Analysts Believe Solid Biosciences (SLDB) Could Rally 198.18%: Here's is How to Trade
SLDB Stock Rallies 60% in a Month: Here's What You Should Know
SLDB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biotech Stock Roundup: MRNA's Q4 Results, GILD's Update & Other News
SLDB Stock Up as FDA Clears IND for SGT-212 in Friedreich's Ataxia
Other News for SLDB
Solid Biosciences (SLDB) Awards Restricted Stock Units to New Employees
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SLDB Stock News
Solid Biosciences reports inducement grants under Nasdaq listing rule
Solid Biosciences (SLDB) Advances Gene Therapy with FDA Fast Track
Solid Biosciences gets FDA fast track status for heart disease therapy